[English]  [Pусский]  [中文]  
 
ctt-journal > Kobzeva et al. (Abstract)

Kobzeva et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract03

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Quality and safety when using cryopreserved umbilical cord blood

Irina V. Kobzeva1, Tatiana A. Astrelina1,2, Mariya V. Yakovleva1, Elena E. Karpova1, Elena V. Skorobogatova3, Olesaya V. Paina4, Lidia L. Lebedeva1,2, Nicolay K. Shakhpazyan1, Elena V. Boyakova1,2, Yanna A. Kruglova1

1Stem Cell Bank, Moscow, Russia; 2Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; 3Russian Children's Clinical Hospital, Moscow, Russia; 4R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, Pavlov State Medical University, St. Petersburg, Russia

Correspondence: Tatiana A. Astrelina, Stem Cell Bank, Moscow, Russia, 31, Bakinskaya str., Moscow, 115541, Russia, E-mail: t_astrelina@spam is badmail.ru

Abstract

Aim: To estimate the quality and safety of umbilical cord blood samples (UCB) for allogeneic hematopoietic stem cell transplantation (HSC) in children.

Methods:
Between 2006 and 2010 44 cryopreserved UCB samples from 37 donors (including 7 divided samples) were given to the cryocomplex "BioArchive". The cryopreservative solution was DMSO/dextran 40 in a final concentration of 10%. All samples were bacteriologically and virally controlled. Before cryopreservation the level of CD34+/CD45+, MNC, and CFU activity (CFU-mix, CFU-(GM+G+M)) was assessed in each UCB sample.

Results: The median number of CD34+/CD45+ cells, MNC, CFU-mix and CFU-(GM +H+M) were 73x105 (42–131.1), 57.3 x107 (48–76), 8,341.665 (2,982.5–14,795) and 21,600 (14,175–33,153) in 1 ml of UCB, respectively. The median cryostorage time for samples was 2 years (1–3). Twenty-four UCB transplants from related and unrelated donors were performed in 23 children with various diseases. HLA-identical donor was 6 (10/10 and 6/6), with mismatch of 1 antigen, 21 (9/10 and 5/6); and of 2 antigens, 10 (8/10 and 4/6). One, 2 and 3 samples of the UCB from different donors were transplanted in 14, 8, and 2 cases respectively. The median volume of UCB was 39.18 (21–44.43) ml, the median dose of MNC and CD34+/CD45+ cells was 16.5 x107 (6.1–19.5) and 7.4 x105 (3.8–10.15) per kg of the recipient respectively. There were no severe adverse reactions to the infusion of UCB. Primary engraftment was in 14 (58.3%) cases, and no engraftment in 10 (41.7%) cases. The median time of granulocytes recovery was 24 days (20–31). Acute GVHD degree I–II developed in 7 cases, and chronic GVHD in one case.
 
Conclusions: The cryopreserved UCB samples are a good source of HSC, capable of restoring hematopoiesis after myeloablative therapy.

Keywords: hematopoietic stem cells, umbilical cord blood, quality, safety, cryopreserved samples, transplantation